97 Over the past decade, the number of biological tools and techniques has proliferated, their capability having improved remarkably. Among others, three enabling technologies stand out: high-throughput proteomics, artificial intelligence, and single-cell sequencing. Their convergence is increasing productivity and efficiency, enhancing precision in Y G healthcare applications, and unlocking substantial economic value. O L O HN C E According to ARK’s research, these technologies could reduce research and development T D N (R&D) spending per drug by more than 25%, potentially increasing the enterprise value of A S L O the precision therapy space 26% at a compound annual rate during the next seven years, O T C from ~$820 billion in 2023 to ~$4.5 trillion in 2030. MI O I T L MU Sources: ARK Investment Management LLC, 2024. This ARK analysis is based on a range of external sources, which may be provided upon request. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.